---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-024646"
form_type: "8-K"
ticker: "NUWE"
cik: "0001506492"
company_name: "Nuwellis, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T17:49:44.932488+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuwellis Q1 revenue up 2% to $1.9M; net loss narrows to $3.8M

## Summary
- Revenue $1.9M, +2% YoY; consumables sales +11% to 82% of total revenue.
- Gross margin 64.1% vs 58.4%; operating loss improved to $4.7M from $5.8M prior year.
- Net loss $3.8M ($0.60 loss per share) vs $6.5M ($5.76 loss per share) YoY.
- Cash $1.4M, no debt; closed $2.7M underwritten public offering on April 30, 2024.
- Plans approx. 50% expense reduction for rest of 2024; launched REVERSE-HF clinical study.

## SEC filing metadata
- accession: 0001140361-24-024646
- form_type: 8-K
- ticker: NUWE
- cik: 0001506492
- company_name: Nuwellis, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506492/000114036124024646/0001140361-24-024646-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506492/000114036124024646/ef20028479_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-024646
- JSON: https://secwatch.observer/filing/0001140361-24-024646.json
- Plain text: https://secwatch.observer/filing/0001140361-24-024646.txt

## Key facts
- Earnings Releases
  Nuwellis, Inc. reported the first quarter ended March 31, 2024 results: revenue $1.9 million, net income $3.8 million, EPS a loss of $0.60 per basic and diluted common share.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $1.9 million
  - Net income: $3.8 million
  - EPS: a loss of $0.60 per basic and diluted common share
  - Result: reported results
  source text: company focused on transforming the lives of people with fluid overload, today reported financial results for the first quarter ended March 31, 2024. Highlights: • Revenue of $1.9 million, a 2% increase over the prior-year period. • Consumables sales, representing 82% of total revenue, grew 11% year-over-year. • Pediatric revenue growth of 40% year over year led
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506492/000114036124024646/0001140361-24-024646-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.